🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "major milestone" in the fight against drug-resistant strains of the infection, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are on the rise worldwide, with data suggesting in excess of 82 million instances annually. Notably increased rates are observed in the African continent and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary development in the reality of growing infection rates, escalating drug resistance and the very limited therapeutic options currently available.”

Medical experts are particularly alarmed about the increase in treatment-resistant strains. The global health body has designated it as a "priority pathogen". Ongoing monitoring revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Receive Clearance

Zoliflodacin, also known as a brand name, was approved by the US FDA in recent days for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Researchers hope that focused deployment of this new drug will help delay the development of resistance.

Gepotidacin, created by the drugmaker GSK, was also approved in close succession. This medication, which is additionally indicated for urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This approval signifies a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Clinical Trial Data and Global Access

Based on findings detailed in a major medical journal, zoliflodacin cured the vast majority of cases of the STI. This establishes an similar efficacy with the typical regimen, which combines a dual-drug approach. The research enrolled over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the ability to license and sell the drug in numerous low-income and middle-income countries.

Doctors on the front lines have voiced positive views. Having a one-pill regimen of this kind is seen as a "critical tool" for gonorrhoea control. This is viewed as crucial to reduce the burden of the infection for patients and to prevent the spread of extremely resistant gonorrhoea worldwide.